NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kaigene Inc.

Kaigene Inc.

Private
Rockville, MarylandHealthcare & Life Scienceshttps://kaigene.us/

Last Round

Pre Seed

Feb 14, 2026

Total Funding Raised

$31.5M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Kaigene Inc. is a biotechnology company that develops innovative antibody therapeutics and fusion proteins to address unmet clinical needs in rare autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

antibody therapeuticsbiotechdrug discoveryautoimmune diseasefusion proteinspathogenic antibody degraderPDEGbiopharmaceutical licensingFcRn inhibitorB-cell suppressionbiotech startuppreclinical researchdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kaigene Inc. Comparables

Compare Kaigene Inc. with similar companies based on industry and business-model similarity.

Kaigene Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
FcR Therapeutics
82%
Cerberus Therapeutics
76%
Viridian Therapeutics
74%

Kaigene Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedFeb 14, 2026
DebtMar 29, 2022

Key People

Founding team and executive leadership

Minjae Shin

Chief Executive Officer President

Executive Team

Kyunghyun Min

Chief Technology Officer

Executive Team

Kaigene Inc. Investors

Notable investors and investment history

Kaigene Inc. investors
InvestorRounds
DSC InvestmentPre Seed
Yuanta InvestmentPre Seed
Korea Development BankPre Seed
CelltrionPre Seed
Sazze PartnersPre Seed
Atinum InvestmentPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 14, 2026

    $30.15M raised from Atinum Investment and others.

Kaigene Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kaigene Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kaigene Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersRockville, Maryland
Employee Range15
Year Founded2022
Last FundingFeb 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.